Related Experiment Video
Updated: Oct 29, 2025
07:52
A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
Published on: November 7, 2017
21.2K
Anemia: A Connection Between Heart Failure and Kidney Failure
Francesco Locatelli1, Lucia Del Vecchio2, Roberto Minutolo3
1Department of Nephrology, Alessandro Manzoni Hospital, Via dell'eremo 9, Lecco 23900, Italy.
Cardiology Clinics
|July 12, 2021
Summary
Erythropoiesis-stimulating agents improve quality of life for chronic kidney disease patients but high doses pose safety risks. Proactive iron therapy may reduce mortality and cardiovascular events, especially with new anemia drugs.
Area of Science:
- Nephrology
- Cardiology
- Hematology
Background:
- Erythropoiesis-stimulating agents (ESAs) enhance quality of life and reduce transfusions in chronic kidney disease (CKD).
- High-dose ESAs targeting normal hemoglobin levels show no benefit and potential safety concerns.
- Iron therapy is crucial for ESA efficacy and may mitigate risks.
Purpose of the Study:
- To review the role of ESAs and iron therapy in managing anemia in CKD.
- To evaluate the cardiovascular implications of ESA treatment and iron supplementation.
- To explore emerging therapies for anemia with improved safety profiles.
Main Methods:
- Review of randomized trials and clinical studies on ESAs and iron therapy.
- Analysis of data concerning hemoglobin levels, transfusion rates, and adverse events.
- Examination of cardiovascular outcomes in patients receiving anemia treatments.
Main Results:
- ESAs improve quality of life but high doses carry risks.
- Proactive iron therapy in hemodialysis patients is linked to reduced mortality and cardiovascular events.
- Intravenous iron therapy shows benefits in heart failure patients.
Conclusions:
- Anemia management in CKD requires careful balancing of ESA efficacy and safety.
- Iron therapy, particularly intravenous, plays a vital role in improving outcomes.
- Novel anemia drugs may offer improved efficacy and reduced cardiovascular risks.
Related Concept Videos
01:27Heart Failure I: Introduction
171
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
171
01:22Heart Failure Drugs: Diuretics
570
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
570
01:17Pathophysiology of Heart Failure
2.1K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.1K
01:29Heart Failure II: Pathophysiology
122
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
122
01:26Heart Failure III: Clinical Manifestations
109
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
109
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
612
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
612